Predictive Biosciences to Present at the 102nd AACR Annual Meeting

04/01/11
Back To Press & Events

 

Lexington, MA – April 1, 2011 – Predictive Biosciences today announced that the Company will be presenting multiple posters on the development of its diagnostic assays for bladder cancer detection at the 102nd American Association for Cancer Research (AACR) Annual Meeting being held April 2 – 6 in Orlando, Florida.

The schedule for the Predictive Biosciences poster presentations is as follows:

Date & Time: Tuesday, April 5, 2011, 8:00 AM ‐12:00 PM

Poster Title: Development of a non‐invasive, multi‐analyte assay for the triage of patients presenting with hematuria.

Lead Author: Cecilia A. Fernandez

Abstract Number: LB‐313

Location: Exhibit Hall A4‐C, Poster Section 40

Session Title: Late‐Breaking Research: Clinical Research 1

Date & Time: Tuesday, April 5, 2011, 1:00 PM ‐ 5:00 PM

Poster Title: Development of a real‐time multiplex PCR assay for the detection of FGFR3 mutations in urine.

Lead Author: John M. Millholland

Abstract Number: 4161

Location: Exhibit Hall A4‐C, Poster Section 14

Session Title: Functional Imaging and Noninvasive Diagnostics
Session Category: Clinical Research 14

Date & Time: Tuesday, April 5, 2011, 1:00 PM ‐ 5:00 PM

Poster Title: Improved PCR amplification of DNA biomarkers with the use of chimeric oligonucleotides.

Lead Author: John M. Millholland

Abstract Number: 3870 Location: Exhibit Hall A4‐C, Poster Section 4 Session Title: Cancer Gene Expression Profiling/Molecular Genetics

Session Category: Cellular and Molecular Biology 53

Following the meeting, the posters will be available in the Posters and Abstracts section of the Predictive Biosciences website at: http://predictivebiosci.com/news_posters‐abstracts.html

Predictive’s portfolio of innovative cancer assays includes the CertNDxTM Molecular Grading Assay, a tissue based test that provides definitive diagnostic and prognostic information for bladder cancer detection, and a new CertNDxTM Bladder Cancer Assay for hematuria assessment that identifies patients with bladder cancer.

Share On Twitter Linkedin